The Effect of a Hospital-wide Urine Culture Screening Intervention on the Incidence of Extended-spectrum β-lactamase-producing Escherichia Coli and Klebsiella Species
Overview
Infectious Diseases
Nursing
Public Health
Authors
Affiliations
Objective: Optimal strategies for limiting the transmission of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp (ESBL-EK) in the hospital setting remain unclear. The objective of this study was to evaluate the impact of a urine culture screening strategy on the incidence of ESBL-EK.
Design: Prospective quasi-experimental study.
Setting: Two intervention hospitals and one control hospital within a university health system from 2005 to 2009.
Patients And Intervention: All clinical urine cultures with E. coli or Klebsiella spp were screened for ESBL-EK. Patients determined to be colonized or infected with ESBL-EK were placed in a private room with contact precautions. The primary outcome of interest was nosocomial ESBL-EK incidence in nonurinary clinical cultures (cases occurring more than 48 hours after admission). Changes in monthly ESBL-EK incidence rates were evaluated with mixed-effects Poisson regression models, with adjustment for institution-level characteristics (eg, total admissions).
Results: The overall incidence of ESBL-EK increased from 1.42/10,000 patient-days to 2.16/10,000 patient-days during the study period. The incidence of community-acquired ESBL-EK increased nearly 3-fold, from 0.33/10,000 patient-days to 0.92/10,000 patient-days (P < .001). On multivariable analysis, the intervention was not significantly associated with a reduction in nosocomial ESBL-EK incidence (incidence rate ratio, 1.38 [95% confidence interval, 0.83-2.31]; P - .21).
Conclusions: Universal screening of clinical urine cultures for ESBL-EK did not result in a reduction in nosocomial ESBL-EK incidence rates, most likely because of increases in importation of ESBL-EK cases from the community. Further studies are needed on elucidating optimal infection control interventions to limit spread of ESBL-producing organisms in the hospital setting.
Saliba R, Zahar J, Dabar G, Riachy M, Karam-Sarkis D, Husni R Pathogens. 2023; 12(1).
PMID: 36678492 PMC: 9866331. DOI: 10.3390/pathogens12010144.
AbiGhosn J, AlAsmar M, Abboud E, Bailey B, Haddad N Cureus. 2022; 14(4):e23849.
PMID: 35530839 PMC: 9071177. DOI: 10.7759/cureus.23849.
Prevel R, Boyer A, Mzali F, Lasheras A, Zahar J, Rogues A Crit Care. 2019; 23(1):170.
PMID: 31088542 PMC: 6518813. DOI: 10.1186/s13054-019-2460-3.
van Duin D, Bonomo R Clin Infect Dis. 2016; 63(2):234-41.
PMID: 27098166 PMC: 4928383. DOI: 10.1093/cid/ciw243.
Suwantarat N, Logan L, Carroll K, Bonomo R, Simner P, Rudin S Infect Control Hosp Epidemiol. 2016; 37(5):535-43.
PMID: 26856439 PMC: 4833541. DOI: 10.1017/ice.2016.16.